<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Ionis Pharmaceuticals Inc — News on 6ix</title>
    <link>https://6ix.com/company/ionis-pharmaceuticals-inc</link>
    <description>Latest news and press releases for Ionis Pharmaceuticals Inc on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Tue, 28 Apr 2026 06:06:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/ionis-pharmaceuticals-inc" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835845378dffbe2df0fd0ef.webp</url>
      <title>Ionis Pharmaceuticals Inc</title>
      <link>https://6ix.com/company/ionis-pharmaceuticals-inc</link>
    </image>
    <item>
      <title>Ionis partner GSK announces bepirovirsen accepted for Priority Review and granted Breakthrough Therapy Designation by U.S. FDA as a potential first-in-class medicine for chronic hepatitis B</title>
      <link>https://6ix.com/company/ionis-pharmaceuticals-inc/news/ionis-partner-gsk-announces-bepirovirsen-accepted-for-priority-review-and-granted-breakthrough-therapy-designation-by-us-fda-as-a-potential-first-in-class-medicine-for-chronic-hepatitis-b</link>
      <guid isPermaLink="true">https://6ix.com/company/ionis-pharmaceuticals-inc/news/ionis-partner-gsk-announces-bepirovirsen-accepted-for-priority-review-and-granted-breakthrough-therapy-designation-by-us-fda-as-a-potential-first-in-class-medicine-for-chronic-hepatitis-b</guid>
      <pubDate>Tue, 28 Apr 2026 06:06:00 GMT</pubDate>
      <description>CARLSBAD, Calif., April 28, 2026--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) partner GSK today announced the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application (NDA) for bepirovirsen, an investigational antisense oligonucleotide (ASO) for the treatment of adults with chronic hepatitis B (CHB). The FDA has granted bepirovirsen Breakthrough Therapy designation and set a Prescription Drug User Fee Act (PDUFA) target action date of October 26, 2026.</description>
    </item>
    <item>
      <title>Ionis presents new data from pivotal study of zilganersen in Alexander disease (AxD) at AAN 2026 Annual Meeting</title>
      <link>https://6ix.com/company/ionis-pharmaceuticals-inc/news/ionis-presents-new-data-from-pivotal-study-of-zilganersen-in-alexander-disease-axd-at-aan-2026-annual-meeting</link>
      <guid isPermaLink="true">https://6ix.com/company/ionis-pharmaceuticals-inc/news/ionis-presents-new-data-from-pivotal-study-of-zilganersen-in-alexander-disease-axd-at-aan-2026-annual-meeting</guid>
      <pubDate>Tue, 21 Apr 2026 11:00:00 GMT</pubDate>
      <description>CARLSBAD, Calif., April 21, 2026--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced additional positive results from the pivotal study of zilganersen in children and adults living with Alexander disease (AxD), a rare, progressive and often fatal neurological condition with no approved disease-modifying treatments. These findings, which will be presented today at the 2026 American Academy of Neurology (AAN) annual meeting, build on previously reported positive topline data and provide a</description>
    </item>
    <item>
      <title>Ionis to hold first quarter 2026 financial results webcast</title>
      <link>https://6ix.com/company/ionis-pharmaceuticals-inc/news/ionis-to-hold-first-quarter-2026-financial-results-webcast</link>
      <guid isPermaLink="true">https://6ix.com/company/ionis-pharmaceuticals-inc/news/ionis-to-hold-first-quarter-2026-financial-results-webcast</guid>
      <pubDate>Wed, 15 Apr 2026 11:05:00 GMT</pubDate>
      <description>CARLSBAD, Calif., April 15, 2026--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host a live webcast on Wednesday, April 29 at 8:30 a.m. Eastern Time to discuss its first quarter 2026 financial results and highlight progress on key programs.</description>
    </item>
    <item>
      <title>Ionis announces zilganersen New Drug Application for Alexander disease (AxD) accepted by FDA for Priority Review</title>
      <link>https://6ix.com/company/ionis-pharmaceuticals-inc/news/ionis-announces-zilganersen-new-drug-application-for-alexander-disease-axd-accepted-by-fda-for-priority-review</link>
      <guid isPermaLink="true">https://6ix.com/company/ionis-pharmaceuticals-inc/news/ionis-announces-zilganersen-new-drug-application-for-alexander-disease-axd-accepted-by-fda-for-priority-review</guid>
      <pubDate>Mon, 23 Mar 2026 04:00:00 GMT</pubDate>
      <description>– PDUFA date set for September 22, 2026 – CARLSBAD, Calif.--(BUSINESS WIRE)-- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that the U.S. Food</description>
    </item>
    <item>
      <title>Ionis announces changes to Board of Directors</title>
      <link>https://6ix.com/company/ionis-pharmaceuticals-inc/news/ionis-announces-changes-to-board-of-directors</link>
      <guid isPermaLink="true">https://6ix.com/company/ionis-pharmaceuticals-inc/news/ionis-announces-changes-to-board-of-directors</guid>
      <pubDate>Mon, 09 Mar 2026 04:00:00 GMT</pubDate>
      <description>– Lynne Parshall and Joseph Wender to retire at end of term in June 2026 and Peter Reikes to join Ionis Board – CARLSBAD, Calif.--(BUSINESS WIRE)-- Ionis</description>
    </item>
    <item>
      <title>Ionis to present new data supporting DAWNZERA™ (donidalorsen) in hereditary angioedema at 2026 AAAAI Annual Meeting</title>
      <link>https://6ix.com/company/ionis-pharmaceuticals-inc/news/ionis-to-present-new-data-supporting-dawnzeratm-donidalorsen-in-hereditary-angioedema-at-2026-aaaai-annual-meeting</link>
      <guid isPermaLink="true">https://6ix.com/company/ionis-pharmaceuticals-inc/news/ionis-to-present-new-data-supporting-dawnzeratm-donidalorsen-in-hereditary-angioedema-at-2026-aaaai-annual-meeting</guid>
      <pubDate>Fri, 27 Feb 2026 05:00:00 GMT</pubDate>
      <description>CARLSBAD, Calif.--(BUSINESS WIRE)-- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced new data to be presented for DAWNZERA™ (donidalorsen), the</description>
    </item>
    <item>
      <title>Olezarsen sNDA accepted by the FDA for Priority Review for the treatment of severe hypertriglyceridemia (sHTG)</title>
      <link>https://6ix.com/company/ionis-pharmaceuticals-inc/news/olezarsen-snda-accepted-by-the-fda-for-priority-review-for-the-treatment-of-severe-hypertriglyceridemia-shtg</link>
      <guid isPermaLink="true">https://6ix.com/company/ionis-pharmaceuticals-inc/news/olezarsen-snda-accepted-by-the-fda-for-priority-review-for-the-treatment-of-severe-hypertriglyceridemia-shtg</guid>
      <pubDate>Thu, 26 Feb 2026 05:00:00 GMT</pubDate>
      <description>– PDUFA date set for June 30, 2026 – CARLSBAD, Calif.--(BUSINESS WIRE)-- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that the U.S. Food and</description>
    </item>
    <item>
      <title>Ionis reports fourth quarter and full year 2025 financial results and highlights progress on key programs</title>
      <link>https://6ix.com/company/ionis-pharmaceuticals-inc/news/ionis-reports-fourth-quarter-and-full-year-2025-financial-results-and-highlights-progress-on-key-programs</link>
      <guid isPermaLink="true">https://6ix.com/company/ionis-pharmaceuticals-inc/news/ionis-reports-fourth-quarter-and-full-year-2025-financial-results-and-highlights-progress-on-key-programs</guid>
      <pubDate>Wed, 25 Feb 2026 05:00:00 GMT</pubDate>
      <description>- TRYNGOLZA® generated $108 million in net product sales in 2025, the first year of launch – - Olezarsen sHTG launch preparations on track, sNDA submitted -</description>
    </item>
    <item>
      <title>Ionis updates time for fourth quarter and full year 2025 financial results webcast</title>
      <link>https://6ix.com/company/ionis-pharmaceuticals-inc/news/ionis-updates-time-for-fourth-quarter-and-full-year-2025-financial-results-webcast</link>
      <guid isPermaLink="true">https://6ix.com/company/ionis-pharmaceuticals-inc/news/ionis-updates-time-for-fourth-quarter-and-full-year-2025-financial-results-webcast</guid>
      <pubDate>Tue, 17 Feb 2026 19:58:00 GMT</pubDate>
      <description>CARLSBAD, Calif., February 17, 2026--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced a change in the start time for its fourth quarter and full year 2025 financial results webcast.</description>
    </item>
    <item>
      <title>Ionis to hold fourth quarter and full year 2025 financial results webcast</title>
      <link>https://6ix.com/company/ionis-pharmaceuticals-inc/news/ionis-hold-fourth-quarter-full-120500976</link>
      <guid isPermaLink="true">https://6ix.com/company/ionis-pharmaceuticals-inc/news/ionis-hold-fourth-quarter-full-120500976</guid>
      <pubDate>Wed, 11 Feb 2026 12:05:00 GMT</pubDate>
      <description>CARLSBAD, Calif., February 11, 2026--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host a live webcast on Wednesday, February 25 at 11:30 a.m. Eastern Time to discuss its fourth quarter and full year 2025 financial results and highlight progress on key programs.</description>
    </item>
    <item>
      <title>DAWNZERA™ (donidalorsen) approved in the European Union for hereditary angioedema (HAE)</title>
      <link>https://6ix.com/company/ionis-pharmaceuticals-inc/news/dawnzeratm-donidalorsen-approved-european-union-hereditary-angioedema-hae-2026-01-21</link>
      <guid isPermaLink="true">https://6ix.com/company/ionis-pharmaceuticals-inc/news/dawnzeratm-donidalorsen-approved-european-union-hereditary-angioedema-hae-2026-01-21</guid>
      <pubDate>Wed, 21 Jan 2026 05:00:00 GMT</pubDate>
      <description>CARLSBAD, Calif.--(BUSINESS WIRE)-- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) and Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announced that the European</description>
    </item>
    <item>
      <title>Ionis well-positioned for continued momentum and substantial value creation in 2026 with two new independent launches and several pivotal data readouts</title>
      <link>https://6ix.com/company/ionis-pharmaceuticals-inc/news/ionis-well-positioned-continued-momentum-and-substantial-value-creation-2026-two-new</link>
      <guid isPermaLink="true">https://6ix.com/company/ionis-pharmaceuticals-inc/news/ionis-well-positioned-continued-momentum-and-substantial-value-creation-2026-two-new</guid>
      <pubDate>Mon, 12 Jan 2026 05:00:00 GMT</pubDate>
      <description>– TRYNGOLZA® (olezarsen) outperforms expectations, achieved 2025 preliminary U.S. net product sales of $105M* as first FDA-approved treatment for FCS; sNDA</description>
    </item>
    <item>
      <title>Ionis partner GSK announces positive topline results from B-Well 1 and B-Well 2 Phase 3 studies for bepirovirsen, a potential first-in-class medicine for chronic hepatitis B</title>
      <link>https://6ix.com/company/ionis-pharmaceuticals-inc/news/ionis-partner-gsk-announces-positive-071500716</link>
      <guid isPermaLink="true">https://6ix.com/company/ionis-pharmaceuticals-inc/news/ionis-partner-gsk-announces-positive-071500716</guid>
      <pubDate>Wed, 07 Jan 2026 07:15:00 GMT</pubDate>
      <description>CARLSBAD, Calif., January 07, 2026--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) partner GSK today announced positive results from two pivotal Phase 3 studies, B-Well 1 and B-Well 2, evaluating the safety and efficacy of bepirovirsen, an investigational antisense oligonucleotide (ASO) for the treatment of chronic hepatitis B (CHB). The studies included over 1,800 patients from 29 countries. GSK licensed bepirovirsen from Ionis and the two companies have collaborated on its development.</description>
    </item>
    <item>
      <title>Ionis to present at 44th Annual J.P. Morgan Healthcare Conference</title>
      <link>https://6ix.com/company/ionis-pharmaceuticals-inc/news/ionis-present-44th-annual-j-120500349</link>
      <guid isPermaLink="true">https://6ix.com/company/ionis-pharmaceuticals-inc/news/ionis-present-44th-annual-j-120500349</guid>
      <pubDate>Tue, 06 Jan 2026 12:05:00 GMT</pubDate>
      <description>CARLSBAD, Calif., January 06, 2026--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that Brett P. Monia, Ph.D., chief executive officer, will...</description>
    </item>
    <item>
      <title>Ionis receives U.S. FDA Breakthrough Therapy designation for zilganersen for Alexander disease (AxD)</title>
      <link>https://6ix.com/company/ionis-pharmaceuticals-inc/news/ionis-receives-us-fda-breakthrough-therapy-designation-zilganersen-alexander-disease</link>
      <guid isPermaLink="true">https://6ix.com/company/ionis-pharmaceuticals-inc/news/ionis-receives-us-fda-breakthrough-therapy-designation-zilganersen-alexander-disease</guid>
      <pubDate>Tue, 02 Dec 2025 05:00:00 GMT</pubDate>
      <description>– First and only investigational medicine for this rare, often fatal neurological condition – – On track to submit new drug application (NDA) in Q1 2026 –</description>
    </item>
    <item>
      <title>Ionis receives U.S. FDA Breakthrough Therapy designation for olezarsen for severe hypertriglyceridemia (sHTG)</title>
      <link>https://6ix.com/company/ionis-pharmaceuticals-inc/news/ionis-receives-us-fda-breakthrough-therapy-designation-olezarsen-severe</link>
      <guid isPermaLink="true">https://6ix.com/company/ionis-pharmaceuticals-inc/news/ionis-receives-us-fda-breakthrough-therapy-designation-olezarsen-severe</guid>
      <pubDate>Mon, 01 Dec 2025 05:00:00 GMT</pubDate>
      <description>– On track to submit supplemental new drug application by end of year – CARLSBAD, Calif.--(BUSINESS WIRE)-- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today</description>
    </item>
    <item>
      <title>DAWNZERA™ (donidalorsen) receives positive opinion from CHMP, recommended for approval in EU for hereditary angioedema (HAE)</title>
      <link>https://6ix.com/company/ionis-pharmaceuticals-inc/news/dawnzeratm-donidalorsen-receives-positive-opinion-chmp-recommended-approval-eu</link>
      <guid isPermaLink="true">https://6ix.com/company/ionis-pharmaceuticals-inc/news/dawnzeratm-donidalorsen-receives-positive-opinion-chmp-recommended-approval-eu</guid>
      <pubDate>Fri, 14 Nov 2025 05:00:00 GMT</pubDate>
      <description>Recommendation based on breadth of clinical evidence demonstrating significant HAE attack rate reduction with DAWNZERA European Commission decision expected</description>
    </item>
    <item>
      <title>Ionis Prices Convertible Notes Offering to Refinance 2026 Convertible Notes</title>
      <link>https://6ix.com/company/ionis-pharmaceuticals-inc/news/ionis-prices-convertible-notes-offering-refinance-2026-convertible-notes-2025-11-13</link>
      <guid isPermaLink="true">https://6ix.com/company/ionis-pharmaceuticals-inc/news/ionis-prices-convertible-notes-offering-refinance-2026-convertible-notes-2025-11-13</guid>
      <pubDate>Thu, 13 Nov 2025 05:00:00 GMT</pubDate>
      <description>- Refinancing transaction with proceeds to be utilized to repurchase or repay the 2026 Convertible Notes prior to or at maturity CARLSBAD, Calif.--(BUSINESS</description>
    </item>
    <item>
      <title>Ionis to present at upcoming investor conferences</title>
      <link>https://6ix.com/company/ionis-pharmaceuticals-inc/news/ionis-present-upcoming-investor-conferences-2025-11-12</link>
      <guid isPermaLink="true">https://6ix.com/company/ionis-pharmaceuticals-inc/news/ionis-present-upcoming-investor-conferences-2025-11-12</guid>
      <pubDate>Wed, 12 Nov 2025 05:00:00 GMT</pubDate>
      <description>CARLSBAD, Calif.--(BUSINESS WIRE)-- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in fireside chats at the</description>
    </item>
    <item>
      <title>Ionis Announces Proposed Convertible Offering to Refinance 2026 Convertible Notes</title>
      <link>https://6ix.com/company/ionis-pharmaceuticals-inc/news/ionis-announces-proposed-convertible-offering-refinance-2026-convertible-notes-2025</link>
      <guid isPermaLink="true">https://6ix.com/company/ionis-pharmaceuticals-inc/news/ionis-announces-proposed-convertible-offering-refinance-2026-convertible-notes-2025</guid>
      <pubDate>Tue, 11 Nov 2025 05:00:00 GMT</pubDate>
      <description>- Refinancing transaction with proceeds to be utilized to repurchase or repay the 2026 Convertible Notes prior to or at maturity CARLSBAD, Calif.--(BUSINESS</description>
    </item>
  </channel>
</rss>